← SynDRA
ENCEQUIDAR
SynDRA canonical compound SYN0039995 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | ABCB1 |
| Mechanism of action | P glycoprotein inhibitor |
All known targets
Mechanisms of action (all sources)
- ABCB1 INHIBITOR
- P-glycoprotein 1 inhibitor
- P glycoprotein inhibitor
- ABCB4 INHIBITOR
Cross-references
Synonyms
- Pgp inhibitor hm30181ak
- HM-30181
- HM30181
- HM30181AK
- HM-30181-A
- UNII-K4I4I996O4
- K4I4I996O4
- 849675-66-7 (free base)
- HM-30181A
- N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide
- HM30181A
- Encequidar [USAN]
- Encequidar (USAN/INN)
- HM-30181 free base
- CHEMBL4594298
- SCHEMBL13822558
- EX-A3429A
- BCP25240
- MFCD25976625
- WHO 10861
- ZINC68014383
- CS-6194
- DB14070
- SB18921
- 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide
- AS-35283
- HY-13646
- D11782
- Q27281950
- 4-oxo-4H-chromen-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide
- 4H-1-Benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-
- N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide
- N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
- ENCEQUIDAR [INN]
- ENCEQUIDAR [WHO-DD]
- P-GLYCOPROTEIN INHIBITOR HM30181AK
- Oraxol (encequidar methanesulfonate + paclitaxel)
- Oratecan (encequidar methanesulfonate + irinotecan)
- encequidarum
Look up ENCEQUIDAR in the interactive SynDRA portal →